2-Oct-2026
No headlines found.
Globe Newswire (Thu, 1-Oct 9:07 AM ET)
Globe Newswire (Wed, 2-Sep 9:15 AM ET)
Definitive Healthcare Appoints Clay Ritchey as CEO
Globe Newswire (Wed, 2-Sep 8:30 AM ET)
Definitive Healthcare Reports Financial Results for Second Quarter 2026
Globe Newswire (Mon, 10-Aug 4:05 PM ET)
Globe Newswire (Thu, 6-Aug 9:05 AM ET)
Globe Newswire (Mon, 3-Aug 4:05 PM ET)
Definitive Healthcare Corp. reports inducement grants under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Mon, 27-Jul 4:05 PM ET)
Definitive Healthcare Corp is a provider of healthcare commercial intelligence. Its SaaS-based healthcare commercial intelligence platform is designed to provide comprehensive and accurate information on the healthcare ecosystem in the U.S. The platform uses deep analytics and data science to help customers develop data-driven strategic decisions, such as finding new markets to enter, building comprehensive go-to-market strategies, accessing tactical information to help target the right decision makers, and improving win rates with detailed contextual information. The company derives substantially all of its revenue from the sale of subscription fees for access to its platform and stand-ready support. Geographically, it derives a majority of its revenue from the United States.
Definitive Healthcare Corp. - Class A trades on the NASDAQ stock market under the symbol DH.
As of October 2, 2026, DH stock price was flat at $0.93 with 205,642 million shares trading.
DH has a beta of 1.88, meaning it tends to be more sensitive to market movements. DH has a correlation of 0.10 to the broad based SPY ETF.
DH has a market cap of $99.62 million. This is considered a Micro Cap stock.
Last quarter Definitive Healthcare Corp. - Class A reported $55 million in Revenue and $.05 earnings per share. This fell short of revenue expectation by $-265,584 and exceeded earnings estimates by $.01.
In the last 3 years, DH traded as high as $10.62 and as low as $.61.
The top ETF exchange traded funds that DH belongs to (by Net Assets): VTI, VXF, DFMC, DFAC, DFAS.
DH has underperformed the market in the last year with a price return of -72.0% while the SPY ETF gained +16.1%. However, in the short term, DH had mixed performance relative to the market. It has outperformed in the last 3 months, returning +19.7% vs +3.6% return in SPY. But in the last 2 weeks, DH shares have been beat by the market, returning -2.8% compared to an SPY return of +1.0%.
DH support price is $.89 and resistance is $.98 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DH shares will trade within this expected range on the day.